Avalyn Pharma Inc.
AVLNHeld by 5 specialist biotech funds
High Convergence5 funds opened new positions. Next phase2 readout (AP02): Dec 2026. Short interest: 5.7% of float.
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kamdar co-founded the enterprise on May 27, 2011, and its corporate headquarters are situated in Boston, Massachusetts.